English

Photocure to Present at Two Investor Conferences in September

Report this content

Press Release – Oslo, Norway September 8, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews and participate in meetings with investors at two upcoming conferences: the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021, and the Danske Bank Securities Life Science Seminar on September 20, 2021.

Presentation Details:

The presentation recording will be available for 90 days from the start of the conference.

The H.C. Wainwright Global Investment Conference features six industry tracks including Healthcare & Biotechnology, as well as leading industry keynote speakers & presenting companies, investor meetings, and networking opportunities.

  • Danske Life Science Seminar: Photocure presents on Monday, September 20 at 3:00pm CET / 9:00am ET. The 2021 Danske Bank Securities Life Science Seminar is an invitational conference series showcasing virtual presentations from life sciences companies to an audience of Swedish and international investors. On September 20, the series will feature companies under the event heading “Life Science Established Growth”.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

 

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO).  For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com

About Hexvix®/Cysview® (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview improves the detection of tumors and leads to more complete resection, fewer residual tumors and better management decisions.

Cysview® is the tradename in the U.S. and Canada, Hexvix® is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe, and has strategic partnerships for the commercialization of Hexvix/Cysview in Canada, Chile, China, Australia and New Zealand. Please refer to https://photocure.com/partnering-with-photocure/our-partners/ for further information on our commercial partners.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Head of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Subscribe

Documents & Links